“The development of TE-1182, an ADC for the treatment of HER2-resistant tumors” was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan. The CDE case number is 115IDX04005.
T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review article introducing our core technology platform “Multi-Arm Linkers”, highlighting its innovative design and broad applications in novel drug development. JCCS is one of Taiwan’s longest-established SCI-indexed chemistry journals. It is published by the Chemical Society
Our Core Technology Platform Published in the Journal of the Chinese Chemical Society Read More »
T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the development of its novel therapeutic pipeline, expand its global strategic presence, and strengthen its capital structure. The company is also actively pursuing international partnership opportunities, with the goal of listing on the Taiwan Emerging Stock
We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the T-E Pharma, have been invited to participate in BIOLOGICS WORLD TAIWAN 2026, to be held in Taiwan, where they will deliver keynote presentations. BIOLOGICS WORLD TAIWAN is Taiwan’s premier annual biotherapeutics industry event, organized by
Join our presentation at the BIOLOGICS WORLD TAIWAN 2026 Read More »
T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future strategic roadmap. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at critical stages of development. Among them, two candidates are expected to advance into Phase II or Phase IIb clinical trials, with
Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma. After achieving remarkable
Great news! Our latest publication presents TE-1146 as a novel therapeutic strategy for the treatment of multiple myeloma. We are thrilled to announce the publication of our paper, entitled “TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity,” in the prestigious journal Haematologica. This study represents a collaborative effort between T-E Meds and
Our Latest Research Published in Haematologica Read More »
